Revenue increased by 16.0% YoY, driven by growth across pharmaceuticals and medical devices, with continued expansion in both domestic and export markets!
In particular, export growth in large and mid-sized pharmaceutical companies was a key driver of overall performance.
R&D expenditure rose by 18.6% YoY, with increases observed across all company sizes.
Operating margin improved to 19.6%, supported by strong profitability in large pharmaceutical companies.
|
